SCOTTSDALE, Ariz., May 8, 2006 (PRIMEZONE) -- Medicis (NYSE:MRX - News) today announced that the U.S. Food and Drug Administration (``FDA'') has approved its New Drug Application (``NDA'') for SOLODYN(TM) (minocycline HCl, USP) Extended Release Tablets. SOLODYN(TM) is the only oral minocycline approved for once daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN(TM) is also the only approved minocycline in extended release tablet form. SOLODYN(TM) is lipid soluble, and its mode of action occurs in the skin and sebum. SOLODYN(TM) is not bioequivalent to any other minocycline products, and is in no way interchangeable with other forms of minocycline.
